Losartan

Drug Profile

Losartan

Alternative Names: Cozaar; Cozaarex; DUP 753; Lortaan; Losaprex; Losartan potassium; MK 954; Neo Lotan; Nu-Lotan; Oscaar

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Banyu; M S Jacovides & Co; Merck & Co; Merck Sharp & Dohme; Neopharmed; S Riesel; sigma-tau SpA
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Heart failure; Hypertension

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Jun 2012 Merck & Co. completes enrolment in its Phase-III trial for Hypertension (in children and infants aged 6 months to 6 years) in USA, European Union, Latin America, India, Norway, Philippines and Russia (NCT00756938)
  • 26 Jan 2012 Generic equivalent available in Canada for Hypertension & Diabetic nephropathies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top